Chromosomal gains and genomic loss of p53 and p16 genes in Barrett's esophagus detected by fluorescence in situ hybridization of cytology specimens

Modern Pathology

Volumn 17, Issue 5, 2004, Pages 588-596

  Fahmy, Mona ^a   Skacel, Marek ^a   Gramlich, Terry L ^a   Brainard, Jennifer A ^a   Rice, Thomas W ^a   Goldblum, John R ^a   Connor, Jason T ^a   Casey, Graham ^a   Legator, Mona S ^b   Tubbs, Raymond R ^a   Falk, Gary W ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b ABBOTT LABORATORIES   (United States)

Author keywords

Barrett's esophagus; Chromosomal gains; Dysplasia; Endoscopic brushing cytology; Fluorescence in situ hybridization; p16 gene; p53 gene

Indexed keywords

BIOLOGICAL MARKER;

ADENOCARCINOMA; ARTICLE; BARRETT ESOPHAGUS; CENTROMERE; CHROMOSOME 11; CHROMOSOME 12; CHROMOSOME 17P; CHROMOSOME 6; CHROMOSOME 7; CHROMOSOME 9P; CONTROLLED STUDY; CYTOLOGY; DIAGNOSTIC VALUE; DYSPLASIA; ENDOSCOPIC BRUSH CYTOLOGY; ENDOSCOPY; ESOPHAGUS BIOPSY; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE LOCUS; GENE LOSS; GENETIC GAIN; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

BARRETT ESOPHAGUS; BIOPSY; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 12; CHROMOSOMES, HUMAN, PAIR 17; CHROMOSOMES, HUMAN, PAIR 6; CHROMOSOMES, HUMAN, PAIR 7; CHROMOSOMES, HUMAN, PAIR 9; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYTODIAGNOSIS; ESOPHAGUS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; NUCLEIC ACID PROBES; SENSITIVITY AND SPECIFICITY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 3042808102     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1038/modpathol.3800088     Document Type: Article

References (45)

1. Falk GW. Barrett's esophagus. Gastroenterology 2002;122:1569-1591 (Review).
2. Werner M, Mueller J, Walch A, et al. The molecular pathology of Barrett's esophagus. Histol Histopathol 1999;14:553-559 (Review).
3. Altorki NK, Oliveria S, Schrump DS. Epidemiology and molecular biology of Barrett's adenocarcinoma. Semin Surg Oncol 1997;13:270-280 (Review).
4. Walch AK, Zitzelsberger HF, Bruch J, et al. Chromosomal imbalances in Barrett's adenocarcinoma and the metaplasia-dysplasia-carcinoma sequence. Am J Pathol 2000;156:555-566.
5. Schmidt HG, Riddell RH, Walther B, et al. Dysplasia in Barrett's esophagus. J Cancer Res Clin Oncol 1985;110:145-152.
6. Nowell PC. The clonal evolution of tumor cell populations. Science 1976;194:23-28.
7. McArdle JE, Lewin KJ, Randall G, et al. Distribution of dysplasias and early invasive carcinoma in Barrett's esophagus. Hum Pathol 1992;23:479-482.
8. Halling KC, King W, Sokolova IA, et al. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol 2000;164:1768-1775.
9. Skacel M, Fahmy M, Brainard JA, et al. Multicolor fluorescence in situ hybridization assay UroVysion detect transitional cell carcinoma in the majority of patients with atypical and negative urinary cytology. J Urol 2003;169:2101-2105.
10. Heselmeyer-Haddad K, Chaudhri N, Stoltzfus P, et al. Detection of chromosomal aneuploidies and gene copy number changes in fine needle aspirates is a specific, sensitive, and objective genetic test for the diagnosis of breast cancer. Cancer Res 2002;62:2365-2369.
11. King BL, Tsai SC, Gryga ME, et al. Detection of chromosomal instability in paired breast surgery and ductal lavage specimens by interphase fluorescence in situ hybridization. Clin Cancer Res 2003;9:1509-1516.
12. Sokolova IA, Bubendorf L, O'Hare A, et al. A fluorescence in situ hybridization-based assay for improved detection of lung cancer cells in bronchial washing specimens. Cancer 2002;96:306-315.
13. O'Sullivan J, Bronner MP, Brentnall TA, et al. Chromosomal instability is related to telomere shortening in a human preneoplastic disease (ulcerative colitis). Nat Genet 2002;32:280-284.
14. Barrett MT, Sanchez CA, Galipeau PC, et al. Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus. Oncogene 1996;13:1867-1873.
15. Huang Y, Boynton RF, Blount PL, et al. Loss of heterozygosity involves multiple tumor suppressor genes in human esophageal cancers. Cancer Res 1992;52:6525-6530.
16. Montesano R, Hollstein M, Hainaut P. Genetic alterations in esophageal cancer and their relevance to etiology and pathogenesis. Int J Cancer 1996;69:225-235 (Review).
17. Neshat K, Sanchez CA, Galipeau PC, et al. Barrett's esophagus: the biology of neoplastic progression. Gastroenterol Clin Biol 1994;18:D71-D76.
18. Neshat K, Sanchez CA, Galipeau PC, et al. p53 mutations in Barrett's adenocarcinoma and high-grade dysplasia. Gastroenterology 1994;106:1589-1595.
19. Schneider PM, Casson AG, Levin B, et al. Mutations of p53 in Barrett's esophagus and Barrett's cancer: a prospective study of ninety-eight cases. J Thorac Cardiovasc Surg 1996;111:323-331.
20. Younes M, Lebovitz RM, Lechago LV, et al. p53 protein accumulation in Barrett's metaplasia, dysplasia, and carcinoma: a follow-up study. Gastroenterology 1993;105:1637-1642.
21. Gleeson CM, Sloan JM, McGuigan JA, et al. Barrett's oesophagus: microsatellite analysis provides evidence to support the proposed metaplasia-dysplasia-carcinoma sequence. Genes Chromosomes Cancer 1998;21:49-60.
22. Persons DL, Croughan WS, Borelli KA, et al. Interphase cytogenetics of esophageal adenocarcinoma and precursor lesions. Cancer Genet Cytogenet 1998;106:11-17.
23. Skacel M, Pettay JD, Tsiftsakis EK, et al. Validation of a multicolor interphase fluorescence in situ hybridization assay for detection of transitional cell carcinoma on fresh and archival thin-layer, liquid-based cytology slides. Anal Quant Cytol Histol 2001;23:381-387.
24. Sokolova IA, Halling KC, Jenkins RB, et al. The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn 2000;2:116-123.
25. Zhou X, McClich DK, Obuchowski NA. Statistical Methods in Diagnostic Medicine. John Wiley & Sons: New York, 2002.
26. Reid BJ, Levine DS, Longton G, et al. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol 2000;95:1669-1676.
27. Reid BJ, Blount PL, Rubin CE, et al. Flow cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort. Gastroenterology 1992;102:1212-1219.
28. Geisinger KR. Endoscopic biopsies and cytologic brushings of the esophagus are diagnostically complementary. Am J Clin Pathol 1995;103:295-299.
29. Falk GW, Chittajallu R, Goldblum JR, et al. Surveillance of Barrett's esophagus for dysplasia and cancer with balloon cytology. Gastroenterology 1997;112:1787-1797.
30. Hardwick RH, Morgan RJ, Warren BF, et al. Brush cytology in the diagnosis of neoplasia in Barrett's esophagus. Dis Esophagus 1997;10:233-237.
31. King W, Proffitt J, Morrison L, et al. The role of fluorescence in situ hybridization technologies in molecular diagnostics and disease management. Mol Diagn 2000;5:309-319 (Review).
32. Zimmermann W, Naumann T, Bauschke E, et al. Comparison of different in situ hybridization techniques for the detection of human papillomavirus DNA in cervical smears. Acta Virol 1991;35:322-331.
33. Cajulis RS, Frias-Hidvegi D, Yu GH, et al. Detection of numerical chromosomal abnormalities by fluorescence in situ hybridization of interphase cell nuclei with chromosome-specific probes on archival cytologic samples. Diagn Cytopathol 1996;14:178-181.
34. Menke-Pluymers MB, van Drunen E, Vissers KJ, et al. Cytogenetic analysis of Barrett's mucosa and adenocarcinoma of the distal esophagus and cardia. Cancer Genet Cytogenet 1996;90:109-117.
35. Garewal HS, Sampliner R, Liu Y, et al. Chromosomal rearrangements in Barrett's esophagus. A premalignant lesion of esophageal adenocarcinoma. Cancer Genet Cytogenet 1989;42:281-296.
36. Moskaluk CA, Hu J, Perlman EJ. Comparative genomic hybridization of esophageal and gastroesophageal adenocarcinomas shows consensus areas of DNA gain and loss. Genes Chromosomes Cancer 1998;22:305-311.
37. Van Dekken H, Geelen E, Dinjens WN, et al. Comparative genomic hybridization of cancer of the gastroesophageal junction: deletion of 14Q31-32.1 discriminates between esophageal (Barrett's) and gastric cardia adenocarcinomas. Cancer Res 1999;59:748-752.
38. Varis A, Puolakkainen P, Savolainen H, et al. DNA copy number profiling in esophageal Barrett's adenocarcinoma: comparison with gastric adenocarcinoma and esophageal squamous cell carcinoma. Cancer Genet Cytogenet 2001;127:53-58.
39. El-Rifai W, Frierson Jr HF, Moskaluk CA, et al. Genetic differences between adenocarcinomas arising in Barrett's esophagus and gastric mucosa. Gastroenterology 2001;121:592-598.
40. Krishnadath KK, Tilanus HW, Alers JC, et al. Detection of genetic changes in Barrett's adencoarcinoma and Barrett's esophagus by DNA in situ hybridization and immunohistochemistry. Cytometry 1994;15:176-184.
41. Krishnadath KK, Tilanus HW, van Blankenstein M, et al. Accumulation of genetic abnormalities during neoplastic progression in Barrett's esophagus. Cancer Res 1995;55:1971-1976.
42. Riegman PH, Vissers KJ, Alers JC, et al. Genomic alterations in malignant transformation of Barrett's eosphagus. Cancer Res 2001;61:3164-3170.
43. Wu TT, Watanabe T, Heitmiller R, et al. Genetic alterations in Barrett esophagus and adenocarcinomas of the esophagus and esophagogastric junction region. Am J Pathol 1998;153:287-294.
44. Doak SH, Jenkins GJ, Parry EM, et al. Chromosome 4 hyperploidy represents an early genetic aberration in premalignant Barrett's oesophagus. Gut 2003;52:623-628.
45. Krishnadath S, Wang K, Halling K, et al. Detection of cytogenetic abnormalities by multi-color FISH in brush cytology specimens of Barrett's esophagus. Gastroenterology 2002;122:M1375A.